LOS ANGELES, CA – [Date of Publication] – A new beacon of hope has emerged for patients grappling with glioblastoma (GBM), one of the most aggressive and intractable forms of brain cancer. Researchers at Keck Medicine of USC have unveiled promising findings from a pioneering study, suggesting an effective combination therapy that could significantly extend survival for individuals diagnosed with this devastating disease. The novel approach integrates Tumor Treating Fields (TTFields) therapy with immunotherapy (pembrolizumab) and traditional chemotherapy (temozolomide), demonstrating a remarkable increase in overall survival, particularly for those with larger, inoperable tumors.
The Glioblastoma Challenge
Glioblastoma stands as a formidable adversary in the world of oncology. According to the National Brain Tumor Society, the average survival for patients diagnosed with glioblastoma is a grim eight months. This stark statistic underscores the critical and urgent need for breakthroughs in treatment. GBM tumors are notoriously aggressive, characterized by rapid growth, a highly infiltrative nature, and a formidable resistance to conventional therapies. They originate in the brain’s supportive glial cells, often forming deep within brain tissue, making complete surgical removal challenging or impossible.
For decades, the standard of care for newly diagnosed glioblastoma has involved surgery, followed by radiation therapy and concomitant chemotherapy with temozolomide. While these treatments can offer a temporary reprieve, the tumor almost invariably recurs, often with increased resistance. Immunotherapy, a revolutionary treatment approach that has transformed the landscape for many other cancer types by harnessing the body’s own immune system, has largely failed to make a significant impact on glioblastoma when used alone. This failure is primarily attributed to the unique biological barriers and immunosuppressive microenvironment inherent to brain tumors, presenting a significant hurdle for researchers worldwide.
The urgent quest for more effective interventions has driven relentless research efforts, seeking to penetrate glioblastoma’s defenses and offer patients a chance at a longer, higher quality of life. The study led by Keck Medicine of USC researchers marks a pivotal moment in this ongoing battle, offering a potential paradigm shift in how this deadly disease is approached.
The Novel Approach
The innovative therapy combines three distinct modalities, each playing a crucial role in a synergistic attack on glioblastoma:
- Tumor Treating Fields (TTFields) therapy: A non-invasive, localized treatment that uses low-intensity alternating electric fields to disrupt cancer cell division.
- Pembrolizumab (Keytruda): An immune checkpoint inhibitor (ICI) that activates the body’s T cells to target and destroy cancer cells.
- Temozolomide (TMZ): A well-established oral chemotherapy agent that damages cancer cell DNA, hindering their growth.
This groundbreaking combination, particularly the integration of TTFields with immunotherapy, appears to create an environment within the tumor that makes it far more susceptible to immune attack—a crucial development given immunotherapy’s prior struggles against GBM.
Chronology
Historical Context of Glioblastoma Treatment
The history of glioblastoma treatment has been one of incremental, often frustrating, progress. Surgical resection, aiming to remove as much of the tumor as safely possible, remains the cornerstone. However, due to the infiltrative nature of GBM cells, microscopic disease invariably remains, leading to recurrence. Radiation therapy was introduced to target these residual cells, followed by the advent of chemotherapy. Temozolomide, approved in the early 2000s, significantly improved outcomes compared to radiation alone, establishing the current standard of care. Despite these advancements, the survival gains were modest, typically extending median survival by only a few months.
More recently, Tumor Treating Fields therapy (marketed as Optune) was approved for glioblastoma in 2015. It offered a novel, non-pharmacological approach to disrupt tumor growth and was often combined with temozolomide. While providing a modest survival benefit, it too faced limitations, and the search for more potent combinations continued. Immunotherapy, which had revolutionized the treatment of melanoma, lung cancer, and other malignancies, was seen as a potential game-changer. However, clinical trials exploring various immune checkpoint inhibitors in glioblastoma, either alone or in combination with chemotherapy or radiation, largely yielded disappointing results. The formidable blood-brain barrier (BBB) and the inherently immunosuppressive microenvironment of glioblastomas were identified as major culprits, effectively shielding the tumor from the body’s immune system and therapeutic agents.
The Genesis of a Hypothesis
Against this backdrop of limited success, Dr. David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study, embarked on a decade-long journey researching TTFields. Dr. Tran theorized that TTFields might possess an unappreciated capacity to not only disrupt tumor growth but also to actively modulate the tumor’s immune microenvironment. His hypothesis centered on the idea that TTFields could create an "in situ immunization" effect directly within the tumor itself, effectively bypassing the blood-brain barrier’s immune-suppressive stronghold.
Dr. Tran envisioned TTFields acting as a "primer," attracting tumor-fighting T cells—a type of white blood cell crucial for immune response—into and around the glioblastoma. This influx of T cells, he hypothesized, would then make the tumor vulnerable to immunotherapy, specifically immune checkpoint inhibitors like pembrolizumab, which work by "unleashing" T cells to attack cancer. Without this initial priming, the immunotherapy would lack sufficient targets within the glioblastoma to be effective. This innovative concept laid the groundwork for the 2-THE-TOP trial, aiming to bridge the critical gap that had previously rendered immunotherapy ineffective against this aggressive brain cancer.
The 2-THE-TOP Phase 2 Trial
The scientific rationale culminated in the design and execution of the 2-THE-TOP, a Phase 2 clinical trial. This critical study enrolled 31 newly diagnosed glioblastoma patients who had completed standard chemoradiation therapy. Out of this cohort, 26 patients received the full triple combination therapy: TTFields combined with both chemotherapy (temozolomide) and immunotherapy (pembrolizumab). A significant subgroup within this trial, seven of these 26 patients, presented with inoperable tumors due to their challenging locations within the brain. This particular subgroup represented an especially high-risk population, traditionally facing the worst prognosis and severely limited treatment options, making their inclusion and subsequent outcomes particularly compelling.
The trial protocol involved patients receiving six to 12 monthly treatments of chemotherapy alongside continuous TTFields therapy for up to 24 months, with the duration adjusted based on individual patient response. The immunotherapy, pembrolizumab, was administered intravenously every three weeks, commencing with the second dose of chemotherapy, also for up to 24 months. The meticulous design of the 2-THE-TOP trial aimed to rigorously assess the safety and preliminary efficacy of this novel triple combination, paving the way for larger-scale validation.
Supporting Data
Unpacking the "Triple Threat" Mechanism
The success of this combination lies in the intricate synergy between its three components, each contributing uniquely to dismantle the glioblastoma’s defenses and empower the body’s immune system.
Tumor Treating Fields (TTFields): The Immune System’s Beacon
At the heart of this innovative approach is Tumor Treating Fields therapy. TTFields deliver low-intensity, alternating electric fields directly into the tumor. These fields are generated by a set of mesh electrodes strategically positioned on the patient’s scalp, ensuring precise frequency and intensity focused on the tumor location. Patients wear these electrodes for approximately 18 hours a day, allowing for continuous therapeutic action.
At a cellular level, TTFields disrupt the fundamental processes of cancer cell division. The alternating electric fields exert mechanical forces on key structures within tumor cells, such as microtubules and polar molecules, continually pushing and pulling them in shifting directions. This mechanical interference makes it exceedingly difficult for the cancer cells to accurately divide and multiply, effectively halting their growth. Beyond this direct anti-proliferative effect, the research unveiled a crucial immune-modulatory role: TTFields were observed to actively attract more tumor-fighting T cells—specialized white blood cells that identify and attack cancer cells—into and around the glioblastoma. This influx of T cells transforms the previously "cold" (immune-deserted) tumor microenvironment into a "hot" (immune-inflamed) one, creating an unprecedented opportunity for immunotherapy to succeed.
Immunotherapy’s Role: Pembrolizumab – Unleashing the Attack
Pembrolizumab, the immunotherapy agent used in this study, belongs to a class of drugs known as immune checkpoint inhibitors (ICIs). These inhibitors work by blocking specific proteins (checkpoints) on immune cells, such as PD-1 (Programmed Death-1) on T cells, or their ligands (PD-L1) on tumor cells. Normally, these checkpoints act as "brakes" to prevent the immune system from overreacting and attacking healthy tissues. However, many cancer cells exploit these checkpoints to evade immune detection and destruction.
By blocking PD-1, pembrolizumab effectively "releases the brakes" on the T cells, allowing them to remain active longer, proliferate, and mount a sustained, aggressive attack against cancer cells. In the context of glioblastoma, however, ICIs alone had previously proven ineffective. This was primarily due to two major challenges: the blood-brain barrier (BBB), which restricts the passage of immune cells and therapeutic agents into the brain, and the inherently immunosuppressive microenvironment within glioblastomas, which actively suppresses any T cells that manage to infiltrate. Dr. Tran’s hypothesis, now supported by data, suggests that TTFields overcome these limitations by creating a hospitable, T-cell-rich environment, enabling pembrolizumab to finally exert its potent anti-cancer effects. Once T cells are attracted by TTFields, immunotherapy ensures they stay active longer and are replaced by even stronger, more effective tumor-fighting T cells.
Chemotherapy (Temozolomide): The Foundation
Temozolomide (TMZ) is an oral alkylating chemotherapy agent that works by adding an alkyl group to DNA, damaging it and leading to cell death. It has been a cornerstone of glioblastoma treatment for decades, typically administered concurrently with radiation and as adjuvant therapy. While effective to a degree, glioblastoma cells often develop resistance over time. In this triple combination, TMZ likely contributes by further weakening tumor cells, making them more susceptible to the combined assault from TTFields and the re-invigorated immune system. It acts as a foundational agent, synergizing with the newer modalities to maximize tumor destruction.
The Breakthrough Results of 2-THE-TOP
The findings from the 2-THE-TOP Phase 2 clinical trial were nothing short of remarkable, offering a significant leap forward in glioblastoma treatment:
- Significant Survival Increase: The study demonstrated a substantial 70% increase in overall survival for patients receiving the triple therapy compared to historical controls.
- Extended Lifespan: Patients who used the device alongside chemotherapy and immunotherapy lived approximately 10 months longer than patients who had previously used TTFields with chemotherapy alone. This direct comparison highlights the crucial contribution of immunotherapy in this combination.
- Hope for Inoperable Tumors: Perhaps the most compelling finding was observed in patients with larger, unresected (not surgically removed) tumors. This subgroup, typically facing the direst prognoses, showed an even stronger immune response to TTFields and lived approximately 13 months longer than patients who underwent surgical removal of their tumors. Dr. Tran theorizes that for kick-starting the body’s immune response against the cancer, having a larger tumor may paradoxically provide more targets for the therapy to work against, leading to a more robust immune activation. This finding could be transformative for patients for whom surgery is not an option, offering a lifeline where none previously existed.
These results are not merely statistically significant; they carry profound clinical implications. Extending survival by 10-13 months in a disease with an average survival of eight months represents a monumental improvement, offering patients and their families precious additional time and quality of life.
Overcoming the Blood-Brain Barrier
A central theme in this research is the ingenious strategy to overcome the blood-brain barrier (BBB) and the immunosuppressive tumor microenvironment, which have historically rendered many glioblastoma therapies ineffective. The BBB is a highly selective physiological barrier that protects the brain from circulating toxins and pathogens but also restricts the entry of most therapeutic agents and immune cells. Glioblastomas further compound this challenge by creating an environment that actively suppresses immune responses, often through the secretion of inhibitory molecules and the recruitment of immune-suppressive cells.
Dr. Tran’s "in situ immunization" approach, driven by TTFields, directly addresses this dual challenge. By attracting T cells into the tumor itself, TTFields essentially create an immune-competent zone within the brain, bypassing the BBB’s restrictive nature. Once these T cells are present, the immunotherapy (pembrolizumab) can then activate and amplify their anti-tumor activity, leading to a potent and sustained immune response directly at the site of the cancer. This synergistic action represents a sophisticated manipulation of the tumor microenvironment, turning a historically immune-privileged site into one susceptible to the body’s own defenses.
Official Responses
Quotes from Dr. David Tran
Dr. David Tran, the visionary behind this research, articulated the significance of these findings with clarity and optimism. "By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before," he stated. His enthusiasm for the potential of this combination is palpable. "Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma."
He further elaborated on the complex interplay of the therapies using a compelling analogy: "Think of it like a team sport – immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This analogy perfectly encapsulates the synergistic mechanism, highlighting how TTFields not only directly damages tumor cells but also makes them vulnerable to the unleashed power of the immune system. Dr. Tran’s decade-long dedication to TTFields research underscores his deep belief in its transformative potential, a belief now strongly supported by the compelling results of this study.
Perspective from Keck Medicine and USC Brain Tumor Center
The success of the 2-THE-TOP trial reflects the collaborative and cutting-edge research environment at Keck Medicine of USC and the USC Brain Tumor Center. Dr. Frances Chow, MD, a neuro-oncologist with USC Norris, who serves as the principal investigator of the Keck Medicine study site, emphasized the institutional commitment to tackling difficult cancers like glioblastoma. "These findings represent a significant step forward in our understanding of how to effectively combat glioblastoma," Dr. Chow noted. "The collaborative spirit and innovative approach taken by Dr. Tran and the entire research team at Keck Medicine of USC are paving the way for improved patient outcomes." The USC Norris Comprehensive Cancer Center, of which Dr. Tran is also a member, provides a robust infrastructure for translating such groundbreaking discoveries from the laboratory to clinical application, reinforcing its position at the forefront of cancer research and patient care.
Broader Scientific Community
The neuro-oncology community has long grappled with the challenges of glioblastoma, and new findings that offer significant survival advantages are met with cautious optimism and keen interest. The results from the Keck Medicine study are anticipated to generate considerable excitement, validating novel approaches that combine physical modalities with biological therapies. Such data encourages further exploration of combination strategies and the re-evaluation of previously unsuccessful monotherapies within a new synergistic framework. The rigorous process of clinical trials, moving from Phase 2 to Phase 3, is a testament to the scientific community’s commitment to robust validation before new treatments become standard of care, ensuring that promising early results translate into tangible benefits for patients globally.
Implications
Hope for the "Untreatable"
The most profound implication of this study lies in the renewed hope it offers, particularly for patients previously deemed to have the bleakest prognoses. The finding that patients with larger, unresected tumors experienced an even stronger immune response and lived longer is truly groundbreaking. For individuals whose tumors are inoperable due to their location or size, surgical removal is not an option, severely limiting their treatment pathways. This study suggests that these very patients, who historically face the shortest survival times, may benefit most from this triple combination therapy. As Dr. Tran stated, "Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option." This opens a critical new avenue for care, transforming despair into tangible possibilities for a segment of the glioblastoma population that has long been underserved.
Reshaping Treatment Paradigms
If validated in the ongoing Phase 3 trial, these findings could fundamentally reshape the standard of care for glioblastoma. The current treatment paradigm, largely established two decades ago, has seen only incremental improvements. The integration of TTFields, immunotherapy, and chemotherapy could lead to a new frontline treatment regimen that significantly improves survival rates and potentially alters the natural history of the disease. This could mean earlier integration of immunotherapy into the treatment sequence, a re-evaluation of the role and timing of surgery, and a broader adoption of TTFields as an indispensable component of combination therapy. The long-term vision is a more personalized and aggressive approach from diagnosis, offering patients a more robust defense against this relentless cancer.
The Path to Phase 3 Validation
The journey from a promising Phase 2 trial to a new standard of care requires rigorous validation in a larger, multicenter Phase 3 clinical trial. Keck Medicine of USC is actively participating in this crucial next step, with Dr. Tran serving as the chair of the steering committee for this global endeavor. This Phase 3 trial, currently open at 28 sites across the United States, Europe, and Israel, aims to enroll over 740 patients through April 2029.
The objectives of this extensive trial are multifaceted:
- Confirm Efficacy: To definitively validate the efficacy and safety of TTFields combined with immunotherapy and chemotherapy on a much larger scale.
- Assess Surgical Impact: To meticulously assess the extent to which surgically removing tumors (gross total resection, partial resection, or biopsy-only tumors) influences the immune response and overall patient outcomes within the context of this triple therapy. This will provide critical insights into whether the "larger tumor, better immune response" observation holds true and its clinical implications.
The successful completion of this Phase 3 trial will be the ultimate determinant of whether this triple combination therapy moves from a promising breakthrough to a widely adopted, life-extending treatment for glioblastoma patients worldwide.
Future Research Avenues
The success of this study also opens numerous avenues for future research. Scientists will undoubtedly explore:
- Optimal Dosing and Schedules: Fine-tuning the frequency, intensity, and duration of TTFields application, as well as the dosing and scheduling of immunotherapy and chemotherapy.
- Biomarkers: Identifying specific biomarkers that can predict which patients are most likely to respond to this combination therapy, enabling more personalized treatment strategies.
- Other Immunotherapies: Investigating whether TTFields can synergize with other types of immunotherapies, potentially leading to even more potent combinations.
- Other Brain Tumor Types: Exploring the applicability of this triple therapy to other aggressive primary or metastatic brain tumors.
- Mechanism Elucidation: Delving deeper into the precise molecular and cellular mechanisms by which TTFields prime the immune microenvironment.
Economic and Accessibility Considerations
While the scientific implications are profound, the practical aspects of cost and accessibility will also need to be addressed. TTFields therapy involves the use of a device that patients wear for most of the day, which can impact daily life and has associated costs. Immunotherapies are also expensive. As this therapy moves towards potential widespread adoption, considerations around healthcare economics, insurance coverage, and global accessibility will become increasingly important to ensure that these life-extending treatments are available to all eligible patients, regardless of their socioeconomic status or geographic location.
Conclusion
The new study from Keck Medicine of USC represents a momentous stride forward in the relentless fight against glioblastoma. By ingeniously combining Tumor Treating Fields therapy, immunotherapy, and chemotherapy, researchers have potentially uncovered a powerful new weapon against a disease that has long defied effective treatment. The ability to extend survival, particularly for those with inoperable tumors, offers a profound message of hope. As the global Phase 3 trial continues to gather crucial data, the scientific and medical communities, alongside patients and their families, will eagerly await its outcomes, with the prospect that this innovative triple therapy could herald a new era in glioblastoma treatment, significantly improving the lives of countless individuals facing this formidable diagnosis. Keck Medicine of USC and its dedicated researchers stand at the vanguard of this transformative potential, continuing to push the boundaries of medical science for the betterment of humanity.
Keck School of Medicine of USC authors of this study include Dongjiang Chen, PhD, assistant professor of research neurological surgery; Son Le, PhD, assistant professor of research neurological surgery; Harshit Manektalia, research programmer; Ming Li, PhD, professor of research population and public health sciences; and Adam O’Dell, research lab specialist. Ashley Ghiaseddin, MD, and Maryam Rahman, MD, MS, colleagues from the University of Florida, also contributed to this work.
This study was funded by a grant from Novocure, which manufactures Optune, the TTFields device used in this study. Tran has received honoraria from Novocure for consultant work. Chen and Tran are inventors of two patent applications related to work reported in this study.
About the Author
